{
  "hypothesis": "h244",
  "title": "Pulmonary Hypertension Drug Transfer to Heart Failure",
  "analysis_date": "2026-02-05",
  "pah_drug_classes": {
    "endothelin_receptor_antagonists": {
      "drugs": [
        "Bosentan",
        "Ambrisentan",
        "Macitentan"
      ],
      "heart_failure_evidence": {
        "ENABLE_trials": {
          "drug": "Bosentan",
          "n": 1613,
          "result": "NEGATIVE",
          "primary_endpoint": "38.8% vs 39.7% (p=0.9)",
          "safety_concerns": "Fluid retention, peripheral edema, weight gain",
          "source": "JACC: Heart Failure 2017"
        },
        "MELODY_trial": {
          "drug": "Macitentan",
          "n": 63,
          "result": "NEGATIVE",
          "notes": "Significant fluid retention in 7/31 macitentan vs 4/32 placebo",
          "source": "Eur Respir J 2018"
        },
        "SERENADE_trial": {
          "drug": "Macitentan",
          "result": "NEGATIVE/HARMFUL",
          "notes": "No benefit, possible harm in HFpEF",
          "source": "Circ Heart Fail 2024"
        }
      },
      "conclusion": "CONTRAINDICATED - Class effect of fluid retention"
    },
    "pde5_inhibitors": {
      "drugs": [
        "Sildenafil",
        "Tadalafil"
      ],
      "heart_failure_evidence": {
        "SilHF_trial": {
          "drug": "Sildenafil",
          "n": 69,
          "result": "NEUTRAL",
          "notes": "Did not improve symptoms, QoL, or exercise capacity vs placebo",
          "limitations": "Underpowered study",
          "source": "Eur J Heart Fail 2022"
        },
        "PASSION_trial": {
          "drug": "Tadalafil",
          "n": 125,
          "result": "ONGOING/INCOMPLETE",
          "population": "HFpEF with pulmonary hypertension",
          "source": "Circulation 2024"
        },
        "earlier_studies": {
          "result": "POSITIVE",
          "notes": "Reduced pulmonary vascular resistance, improved exercise capacity",
          "limitations": "Single-center studies"
        }
      },
      "conclusion": "INCONCLUSIVE - Mixed results, no large positive trials"
    },
    "sgc_stimulators": {
      "drugs": [
        "Riociguat",
        "Vericiguat"
      ],
      "heart_failure_evidence": {
        "DYNAMIC_trial": {
          "drug": "Riociguat",
          "result": "MIXED",
          "hemodynamics": "Improved cardiac output at rest",
          "symptoms": "No change in clinical symptoms",
          "source": "Eur Heart J 2022"
        },
        "VICTORIA_trial": {
          "drug": "Vericiguat",
          "n": 5050,
          "result": "POSITIVE",
          "primary_endpoint": "35.5% vs 38.5% (p=0.02)",
          "effect_size": "10% reduction in CV death + HF hospitalization",
          "fda_approval": "January 2021",
          "source": "NEJM 2020"
        }
      },
      "conclusion": "VALIDATED via Vericiguat - FDA approved for HFrEF"
    },
    "prostacyclin_analogs": {
      "drugs": [
        "Epoprostenol",
        "Treprostinil",
        "Iloprost",
        "Selexipag"
      ],
      "heart_failure_evidence": {
        "FIRST_trial": {
          "drug": "Epoprostenol",
          "result": "HARMFUL",
          "notes": "INCREASED MORTALITY - trial terminated early",
          "source": "Historical"
        },
        "current_status": "CONTRAINDICATED in systolic heart failure"
      },
      "conclusion": "CONTRAINDICATED - Increased mortality risk"
    }
  },
  "model_predictions_validated": {
    "true_positives": {
      "sgc_stimulator_class": {
        "predicted": [
          "Riociguat"
        ],
        "validated_by": "Vericiguat FDA approval (same mechanism)",
        "precision_implication": "Model correctly identifies sGC stimulator mechanism"
      }
    },
    "true_negatives_missed": {
      "should_have_been_filtered": [
        {
          "drug": "Bosentan",
          "reason": "Fluid retention risk"
        },
        {
          "drug": "Ambrisentan",
          "reason": "Fluid retention risk"
        },
        {
          "drug": "Macitentan",
          "reason": "Fluid retention, possible harm"
        },
        {
          "drug": "Epoprostenol",
          "reason": "INCREASED MORTALITY"
        },
        {
          "drug": "Treprostinil",
          "reason": "Class effect - mortality concern"
        },
        {
          "drug": "Iloprost",
          "reason": "Class effect - mortality concern"
        },
        {
          "drug": "Selexipag",
          "reason": "Class effect - mortality concern"
        }
      ]
    }
  },
  "key_findings": [
    "1. Model correctly predicts sGC stimulator mechanism (Riociguat\u2192HF) - VALIDATED by Vericiguat approval",
    "2. Model INCORRECTLY predicts endothelin antagonists (Bosentan, etc.) - Fluid retention risk",
    "3. Model INCORRECTLY predicts prostacyclin analogs - INCREASED MORTALITY in FIRST trial",
    "4. PDE5 inhibitors (Sildenafil, Tadalafil) remain inconclusive - no large positive trials",
    "5. Critical insight: Same target class may have opposite effects (sGC stimulators vs prostacyclins)"
  ],
  "production_recommendations": [
    "ADD TO CONFIDENCE FILTER: Endothelin receptor antagonists for heart failure (fluid retention)",
    "ADD TO CONFIDENCE FILTER: Prostacyclin analogs for systolic heart failure (mortality risk)",
    "RETAIN: sGC stimulator predictions for heart failure (Vericiguat-validated mechanism)",
    "DOWNGRADE: PDE5 inhibitor predictions for heart failure (inconclusive evidence)"
  ],
  "hypothesis_status": "VALIDATED",
  "validation_type": "mixed - partial validation with important contraindications discovered"
}